AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

Claims 1-67. (Canceled)

68. (Original) A cell line derived from a B-cell line which is adapted for serum-free culture and in which the EBNA-1 gene of Epstein-Barr virus is expressed, where at least one of the following (1) to (3) is integrated into a chromosomal DNA:

(1) DNA construct for expression of a transcription factor necessary for construction of an inducible expression system;

(2) DNA construct where a reporter gene is ligated at the downstream area of a promoter having a responsive element of a transcription factor; and

(3) DNA construct for expression of Gα protein or a chimeric Gα protein.

69. (Original) The cell line according to claim 68, wherein the cell line is a Namalwa cell adapted for serum-free culture.

70. (Original) The cell line according to claim 69, wherein the Namalwa cell adapted for serum-free culture is Namalwa KJM-1 cell.

71. (Original) The cell line according to claim 68, wherein the transcription factor necessary for construction of the inducible expression system is a chimeric protein of a ligand binding domain of estrogen receptor and yeast Gal4p.

72. (Original) The cell line according to claim 68, wherein the responsive element of the transcription factor is cAMP responsive element (CRE), TPA responsive element (TRE), NFAT (nuclear factor of activated T cells) responsive element or serum responsive element (SRE).

73. (Original) The cell line according to claim 68, wherein the reporter gene is firefly luciferase gene, *Renilla reniformis* luciferase gene, chloramphenicol acetyltransferase gene, β-galactosidase gene, β-lactamase gene or green fluorescent protein gene.

74. (Original) The cell line according to claim 68, wherein the Gα protein is at least one Gα protein selected from the group consisting of $G\alpha_{16}$, $G\alpha_{15}$, $G\alpha_q$, $G\alpha_{11}$, $G\alpha_s$, $G\alpha_i$, $G\alpha_o$, $G\alpha_z$, $G\alpha_{12}$, $G\alpha_{13}$, $G\alpha_{gust}$, $G\alpha_t$ and $G\alpha_{14}$.

75. (Original) The cell line according to claim 68, wherein the chimeric Gα protein is at least one chimeric Gα protein selected from the group consisting of the following (1) to (20):

(1) chimeric Gα protein where C-terminal 5 amino acids of $G\alpha_s$ are substituted with C-terminal 5 amino acids of $G\alpha_q$;

(2) chimeric Gα protein where C-terminal 5 amino acids of $G\alpha_s$ are substituted with C-terminal 5 amino acids of $G\alpha_i$;

(3) chimeric Gα protein where C-terminal 5 amino acids of $G\alpha_s$ are substituted with C-terminal 5 amino acids of $G\alpha_o$;

(4) chimeric Gα protein where C-terminal 5 amino acids of $G\alpha_s$ are substituted with C-terminal 5 amino acids of $G\alpha_z$;

(5) chimeric Gα protein where C-terminal 5 amino acids of $G\alpha_s$ are substituted with C-terminal 5 amino acids of $G\alpha_{12}$;

(6) chimeric Gα protein where C-terminal 5 amino acids of $G\alpha_s$ are substituted with C-terminal 5 amino acids of $G\alpha_{13}$;

(7) chimeric Gα protein where C-terminal 5 amino acids of $G\alpha_s$ are substituted with C-terminal 5 amino acids of $G\alpha_{gust}$;

(8) chimeric Gα protein where C-terminal 5 amino acids of $G\alpha_s$ are substituted with C-terminal 5 amino acids of $G\alpha_t$;

(9) chimeric Gα protein where C-terminal 5 amino acids of $G\alpha_s$ are substituted with C-terminal 5 amino acids of $G\alpha_{14}$;

(10) chimeric Gα protein where C-terminal 5 amino acids of $G\alpha_s$ are substituted with C-terminal 5 amino acids of $G\alpha_{16}$;

(11) chimeric Gα protein where C-terminal 5 amino acids of $G\alpha_q$ are substituted with C-terminal 5 amino acids of $G\alpha_s$;

(12) chimeric Gα protein where C-terminal 5 amino acids of $G\alpha_q$ are substituted with C-terminal 5 amino acids of $G\alpha_i$;

(13) chimeric Gα protein where C-terminal 5 amino acids of $G\alpha_q$ are substituted with C-terminal 5 amino acids of $G\alpha_o$;

(14) chimeric Gα protein where C-terminal 5 amino acids of $G\alpha_q$ are substituted with C-terminal 5 amino acids of $G\alpha_z$;

(15) chimeric Gα protein where C-terminal 5 amino acids of $G\alpha_q$ are substituted with C-terminal 5 amino acids of $G\alpha_{12}$;

(16) chimeric Gα protein where C-terminal 5 amino acids of $G\alpha_q$ are substituted with C-terminal 5 amino acids of $G\alpha_{13}$;

(17) chimeric Gα protein where C-terminal 5 amino acids of $G\alpha_q$ are substituted with C-terminal 5 amino acids of $G\alpha_{gust}$;

(18) chimeric Gα protein where C-terminal 5 amino acids of $G\alpha_q$ are substituted with C-terminal 5 amino acids of $G\alpha_t$;

(19) chimeric Gα protein where C-terminal 5 amino acids of $G\alpha_q$ are substituted with C-terminal 5 amino acids of $G\alpha_{14}$; and

(20) chimeric Gα protein where C-terminal 5 amino acids of $G\alpha_q$ are substituted with C-terminal 5 amino acids of $G\alpha_{16}$.

76. (Original) The cell line according to claim 68, wherein the transcription factor necessary for construction of the inducible expression system is a chimeric protein of a ligand binding domain of estrogen receptor and yeast Gal4p, the promoter having a responsive element of the transcription factor is a promoter having a cAMP responsive element (CRE) and the reporter gene is firefly luciferase gene or *Renilla reniformis* luciferase gene.

77. (Original) The cell line according to claim 68, wherein the transcription factor necessary for construction of the inducible expression system is a chimeric protein of a ligand binding domain of estrogen receptor and yeast Gal4p, the promoter having a responsive element of the transcription factor is a promoter having a cAMP responsive element (CRE), the reporter gene is firefly luciferase gene or *Renilla reniformis* luciferase gene and the chimeric Gα protein is a chimeric Gα protein where C-terminal 5 amino acids of $G\alpha_s$ are substituted with C-terminal 5 amino acids of $G\alpha_q$ or a chimeric

$G\alpha$ protein where C-terminal 5 amino acids of $G\alpha_s$ are substituted with C-terminal 5 amino acids of $G\alpha_i$.

Claims 78-108. (Canceled)